GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002260410 | Cervix | CC | regulation of cell morphogenesis | 84/2311 | 309/18723 | 1.00e-12 | 4.29e-10 | 84 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
GO:00514038 | Cervix | CC | stress-activated MAPK cascade | 55/2311 | 239/18723 | 2.96e-06 | 8.31e-05 | 55 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
GO:00160498 | Cervix | CC | cell growth | 92/2311 | 482/18723 | 1.16e-05 | 2.49e-04 | 92 |
GO:00325359 | Cervix | CC | regulation of cellular component size | 76/2311 | 383/18723 | 1.66e-05 | 3.21e-04 | 76 |
GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
GO:00719025 | Cervix | CC | positive regulation of protein serine/threonine kinase activity | 46/2311 | 200/18723 | 1.87e-05 | 3.47e-04 | 46 |
GO:00434104 | Cervix | CC | positive regulation of MAPK cascade | 90/2311 | 480/18723 | 2.92e-05 | 4.83e-04 | 90 |
GO:00181057 | Cervix | CC | peptidyl-serine phosphorylation | 63/2311 | 315/18723 | 6.65e-05 | 9.47e-04 | 63 |
GO:00182096 | Cervix | CC | peptidyl-serine modification | 66/2311 | 338/18723 | 9.58e-05 | 1.25e-03 | 66 |
GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
GO:00459277 | Cervix | CC | positive regulation of growth | 53/2311 | 259/18723 | 1.33e-04 | 1.64e-03 | 53 |
GO:00015588 | Cervix | CC | regulation of cell growth | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0453026 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0472216 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
hsa0516626 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa04530112 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0472217 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
hsa05166111 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa0453027 | Endometrium | EEC | Tight junction | 54/1237 | 169/8465 | 6.56e-09 | 1.27e-07 | 9.46e-08 | 54 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0516627 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa0472222 | Endometrium | EEC | Neurotrophin signaling pathway | 30/1237 | 119/8465 | 1.54e-03 | 9.55e-03 | 7.12e-03 | 30 |
hsa0453036 | Endometrium | EEC | Tight junction | 54/1237 | 169/8465 | 6.56e-09 | 1.27e-07 | 9.46e-08 | 54 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0516636 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa0472232 | Endometrium | EEC | Neurotrophin signaling pathway | 30/1237 | 119/8465 | 1.54e-03 | 9.55e-03 | 7.12e-03 | 30 |
hsa0412018 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
hsa0453028 | Prostate | BPH | Tight junction | 68/1718 | 169/8465 | 1.70e-09 | 2.55e-08 | 1.58e-08 | 68 |
hsa0516628 | Prostate | BPH | Human T-cell leukemia virus 1 infection | 79/1718 | 222/8465 | 6.00e-08 | 6.83e-07 | 4.23e-07 | 79 |
hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K1 | insertion | Frame_Shift_Ins | novel | c.4199_4200dupCT | p.Gly1401LeufsTer22 | p.G1401Lfs*22 | Q13233 | protein_coding | | | TCGA-AJ-A3OL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
MAP3K1 | insertion | Frame_Shift_Ins | novel | c.932dupT | p.Met312AspfsTer14 | p.M312Dfs*14 | Q13233 | protein_coding | | | TCGA-AJ-A8CW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K1 | deletion | Frame_Shift_Del | novel | c.4023_4080delNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Lys1342MetfsTer16 | p.K1342Mfs*16 | Q13233 | protein_coding | | | TCGA-AP-A0LS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K1 | deletion | Frame_Shift_Del | novel | c.3231delN | p.Asn1079IlefsTer3 | p.N1079Ifs*3 | Q13233 | protein_coding | | | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K1 | deletion | Frame_Shift_Del | novel | c.3231delN | p.Asn1079IlefsTer3 | p.N1079Ifs*3 | Q13233 | protein_coding | | | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K1 | deletion | Frame_Shift_Del | novel | c.4073delN | p.Ser1358CysfsTer19 | p.S1358Cfs*19 | Q13233 | protein_coding | | | TCGA-AX-A2HG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K1 | deletion | Frame_Shift_Del | | c.1846delN | p.Gly617GlufsTer39 | p.G617Efs*39 | Q13233 | protein_coding | | | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP3K1 | insertion | In_Frame_Ins | novel | c.3496_3497insTCTTCT | p.Thr1166delinsIlePheSer | p.T1166delinsIFS | Q13233 | protein_coding | | | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD |
MAP3K1 | insertion | Frame_Shift_Ins | novel | c.3498_3499insA | p.Tyr1167IlefsTer4 | p.Y1167Ifs*4 | Q13233 | protein_coding | | | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD |
MAP3K1 | insertion | In_Frame_Ins | novel | c.1254_1255insAAAGAGTTAAAAAGAAAA | p.Ser418_His419insLysGluLeuLysArgLys | p.S418_H419insKELKRK | Q13233 | protein_coding | | | TCGA-B5-A11V-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | cisplatin | CISPLATIN | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | gefitinib | GEFITINIB | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | paclitaxel | PACLITAXEL | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 223366167 | E-6201 | |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | docetaxel | DOCETAXEL | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | erlotinib | ERLOTINIB | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | CHEMBL1097999 | E-6201 | |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | carboplatin | CARBOPLATIN | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | CI-1040 | CI-1040 | |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | Tumor necrosis factor alpha (TNF-alpha) inhibitors | | 27670765 |